KRAS and familial pancreatic carcinoma: Increased SRC expression positively correlates with chemoresistance in human pancreatic cancer cell lines [126], while oncogenic KRAS mutations induce a SRC-dependent amplification loop that promotes metastasis and therapy resistance in human PDAC tumors [127].